Blood-filter treatment during heart transplant surgery
Part of Heart & circulation clinical trials.
This study tests whether a blood-filter treatment used during a heart transplant can improve how the transplant goes for adults. You might be eligible if you’re having a heart transplant and meet the specific medication and procedure requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and scheduled for a heart transplant
- You agree to and sign informed consent (you cannot decline)
- You are not taking anti-leukocyte medicines
- You are not receiving TNF-alpha blockers or certain immune-suppressing medicines (for example, tocilizumab)
- You are not using donor heart donation after circulatory death (DCD)
- This is not an ex-vivo (outside the body) heart perfusion procedure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This study looks at how well donor hearts work and how that affects outcomes after heart transplantation. It may help transplant teams choose and use donor hearts more effectively.
This trial looks at how a blood-filtering treatment called hemoadsorption affects patients' health and lab results. It may help people who are already receiving this therapy.
This study tests whether adding a special filter (called a cytokine adsorber) to the heart-lung machine during your child's open-heart surgery can reduce harmful inflammation and help them recover better. The filter is used alongside the standard heart-lung machine during the operation.
This trial tests a special blood filter used during children's heart surgery to reduce inflammation. It may help children recover faster after long operations.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Hear when a new Heart Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.